Sunday, 18 October 2026 | Lusaka, Zambia | All times CAT
Updated 2 hours ago Topics Journalists Our network Advertise
Lakatips Sourcing the truth from every corner of Zambia

Lakatips

Advertise on Lakatips

Reach readers following the national conversation

Display, sponsored placements and briefing slots — across politics, business and sport.

See the options
Just in

Politics

Bad News for Zimbabwe as the United States Ends Health Funding for Key HIV, Tuberculosis and Malaria Programmes after Harare Rejects a Proposed Health Agreement over Data-Sharing and Sovereignty Concerns

United States has announced that it will end funding for Zimbabwe’s health programmes at the end of September following the collapse of negotiations over

BAD NEWS FOR ZIMBABWE AS THE UNITED STATES ENDS HEALTH FUNDING FOR KEY HIV, TUBERCULOSIS AND MALARIA PROGRAMMES AFTER HARARE REJECTS A PROPOSED HEALTH AGREEMENT OVER DATA-SHARING AND SOVEREIGNTY CONCERNS The United States has announced that it will end funding for Zimbabwe’s health programmes at the end of September following the collapse of negotiations over […]

The post BAD NEWS FOR ZIMBABWE AS THE UNITED STATES ENDS HEALTH FUNDING FOR KEY HIV, TUBERCULOSIS AND MALARIA PROGRAMMES AFTER HARARE REJECTS A PROPOSED HEALTH AGREEMENT OVER DATA-SHARING AND SOVEREIGNTY CONCERNS first appeared on The Zambian Observer

Source: Zambian Observer — Read more

More to read

All Politics →

Malarial drug for infants recalled over potential treatment failure.

GOVERNMENT has recalled a drug used for the treatment of malaria in young children after it was discovered that the medicine contained less active ingredient than required. Speaking while delivering a ministerial statement on the recall, Minister of Health Elijah Muchima said during routine surveillance…

Mwebantu •
One-time sign-up

Keep reading at Zambian Observer

Lakatips is free, and it stays free. Sign up once and we will send you through to Zambian Observer — and to every other newsroom in the network after that, without asking again.

We use your details for the morning briefing and to tell newsrooms how many readers we send them — never as a list to be sold on. See our privacy policy.